Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. Reply

Affiliations

¹ Cleveland Clinic, Cleveland, OH kleina@ccf.org.
² Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.
³ Kiniksa Pharmaceuticals, Lexington, MA.

Comment

Allan L Klein et al. N Engl J Med. 2021.

. 2021 Apr 15;384(15):1475-1476.

doi: 10.1056/NEJMc2101978.

¹ Cleveland Clinic, Cleveland, OH kleina@ccf.org.
² Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.
³ Kiniksa Pharmaceuticals, Lexington, MA.

No abstract available

Comment on

Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.
Tabor E. Tabor E. N Engl J Med. 2021 Apr 15;384(15):1474. doi: 10.1056/NEJMc2101978. N Engl J Med. 2021. PMID: 33852789 No abstract available.
Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.
Lazaros G, Tsioufis K, Vassilopoulos D. Lazaros G, et al. N Engl J Med. 2021 Apr 15;384(15):1474-1475. doi: 10.1056/NEJMc2101978. N Engl J Med. 2021. PMID: 33852790 No abstract available.